STOCK TITAN

Bio-Techne Corp - TECH STOCK NEWS

Welcome to our dedicated page for Bio-Techne news (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne stock.

Bio-Techne Corporation (NASDAQ: TECH) provides this centralized hub for investors and industry professionals tracking developments in life sciences innovation. Access official press releases, financial disclosures, and strategic updates from the global leader in bioactive reagents and diagnostic solutions.

This resource delivers timely updates on earnings results, product launches, and strategic collaborations critical to understanding the company's position in biotechnology markets. Users will find announcements related to protein analysis advancements, spatial biology innovations, and global distribution partnerships.

All content is sourced directly from Bio-Techne's corporate communications, ensuring accuracy for those monitoring investment opportunities or industry trends. Bookmark this page for efficient access to material developments affecting TECH's market performance and scientific impact.

Rhea-AI Summary
Bio-Techne (NASDAQ: TECH) has filed a patent infringement lawsuit against Molecular Instruments, Inc. in Europe to protect its patented RNAscope® ISH technology. The lawsuit alleges that Molecular Instruments' HCR 3.0 technology infringes ACD's European Patents 1,910,572 and 2,500,439. Bio-Techne aims to halt the infringement, seek damages, and obtain injunctive relief in key European markets to defend its position as a global leader in spatial biology research and clinical applications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
none
-
Rhea-AI Summary
Bio-Techne (NASDAQ: TECH) will host a conference call on May 1, 2024, to review third quarter fiscal 2024 financial results. Bio-Techne is a leading developer of high-quality purified proteins, reagent solutions, and diagnostic products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.41%
Tags
conferences earnings
-
Rhea-AI Summary
Bio-Techne (NASDAQ: TECH) announces that Advanced Cell Diagnostics (ACD) has reached a milestone of over 10,000 peer-reviewed publications utilizing RNAscope™ ISH technology, solidifying its leadership in spatial biology applications. The increasing global customer awareness and market adoption signify ACD's significant impact in enabling ground-breaking biologic discoveries and therapeutic advancements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
none
Rhea-AI Summary
Bio-Techne (TECH) will present its cancer research solutions at the AACR annual meeting in April 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
conferences
-
Rhea-AI Summary
Bio-Techne (TECH) wins prestigious awards for its R&D Systems and Advanced Cell Diagnostics brands. The company received the 'ELISA Kit Supplier of the Year' award for its R&D Systems brand and 'The Innovation Award' for Advanced Cell Diagnostics. These accolades highlight Bio-Techne's commitment to scientific excellence and innovation in the research and clinical diagnostic communities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
none
-
Rhea-AI Summary
Bio-Techne (NASDAQ: TECH) announces a partnership between Lunaphore and Nikon to expand access to spatial biology services in the US. The collaboration aims to provide cutting-edge technology for researchers and clinicians to enhance spatial biology research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
partnership
Rhea-AI Summary
Bio-Techne's QuantideX qPCR BCR-ABL IS Kit is now compliant with the latest EU diagnostic regulations, enhancing monitoring for CML patients. The kit offers robust quantification of BCR-ABL1 and ABL1 transcripts, aiding in TKI therapy response assessment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.15%
Tags
none
-
Rhea-AI Summary
Bio-Techne Corporation (NASDAQ: TECH) will have its President, Will Geist, present at the KeyBanc Life Sciences & MedTech Investor Forum on March 19, 2024. The presentation will be available via a live webcast on the company's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.34%
Tags
conferences
-
Rhea-AI Summary
Bio-Techne Corporation (TECH) President and CEO to present at Barclays Global Healthcare Conference. Live webcast available on Bio-Techne's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
conferences
Rhea-AI Summary
Bio-Techne Corporation (NASDAQ: TECH) reported second-quarter financial results, showing a 2% organic revenue decline to $272.6 million, with GAAP EPS at $0.17 and adjusted EPS at $0.40. The company experienced growth in instrument consumables and academic end markets, but saw a decrease in operating income and margin. The Diagnostics and Genomics segment saw a 11% increase in net sales, but a decrease in operating margin due to the Lunaphore acquisition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.53%
Tags
Bio-Techne Corp

Nasdaq:TECH

TECH Rankings

TECH Stock Data

7.60B
156.43M
1.05%
101.12%
3.33%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
MINNEAPOLIS